Does Acelrx Pharmaceuticals Inc (NASDAQ:ACRX) Have Gas After Even Less Sellers Involved?

March 16, 2018 - By Darrin Black

 Does Acelrx Pharmaceuticals Inc (NASDAQ:ACRX) Have Gas After Even Less Sellers Involved?

Investors sentiment decreased to 0.7 in Q3 2017. Its down 0.05, from 0.75 in 2017Q2. It is negative, as 12 investors sold AcelRx Pharmaceuticals, Inc. shares while 15 reduced holdings. 8 funds opened positions while 11 raised stakes. 6.65 million shares or 37.02% less from 10.56 million shares in 2017Q2 were reported.
Element Cap Mngmt Limited Liability Corporation invested in 21,540 shares or 0.04% of the stock. Barclays Public Limited Company stated it has 56,473 shares or 0% of all its holdings. Moreover, Blackrock Incorporated has 0% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Geode Cap Mgmt Limited Liability Co holds 0% of its portfolio in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 215,834 shares. Raymond James & Associate holds 46,000 shares. Northern Tru invested 0% of its portfolio in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). National Bank Of America De invested 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Meeder Asset Management Incorporated, a Ohio-based fund reported 1,120 shares. Federated Investors Pa holds 787 shares or 0% of its portfolio. National Bank Of New York Mellon Corp owns 67,961 shares. 32,318 were reported by Royal Natl Bank Of Canada. France-based Natixis has invested 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Manufacturers Life Company The invested in 0% or 2,590 shares. Wells Fargo & Mn accumulated 8,995 shares. Guggenheim Cap Ltd Liability Corporation holds 0% or 11,997 shares.

Since October 2, 2017, it had 0 insider purchases, and 1 insider sale for $53,752 activity.

The stock of Acelrx Pharmaceuticals Inc (NASDAQ:ACRX) registered a decrease of 4.26% in short interest. ACRX’s total short interest was 4.56 million shares in March as published by FINRA. Its down 4.26% from 4.77 million shares, reported previously. With 303,600 shares average volume, it will take short sellers 15 days to cover their ACRX’s short positions. The short interest to Acelrx Pharmaceuticals Inc’s float is 12.35%.

It closed at $2.075 lastly. It is down 14.24% since March 16, 2017 and is downtrending. It has underperformed by 30.94% the S&P500.

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company has market cap of $105.62 million. The Company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet, which is in Phase III clinical trial for the treatment of moderate-to-severe acute pain. It currently has negative earnings. The companyÂ’s late-stage investigational product candidate is Zalviso, a pre-programmed and patient-controlled analgesia device that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Ratings Coverage

Among 8 analysts covering AcelRx Pharmaceuticals (NASDAQ:ACRX), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. AcelRx Pharmaceuticals had 21 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Buy” rating by TH Capital given on Thursday, September 15. The stock has “Buy” rating by RBC Capital Markets on Friday, August 25. Jefferies downgraded the stock to “Hold” rating in Friday, October 13 report. The firm has “Buy” rating by Roth Capital given on Monday, October 5. The stock has “Hold” rating by Jefferies on Tuesday, November 14. The company was maintained on Friday, August 4 by H.C. Wainwright. The stock has “Buy” rating by TH Capital on Monday, October 5. On Tuesday, August 1 the stock rating was maintained by Cowen & Co with “Hold”. The firm has “Buy” rating by Jefferies given on Friday, July 14. The company was maintained on Wednesday, August 2 by Roth Capital.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.